Therapeutic Efficacy of Six Proprietary Chinese Medicines Combined with Entecavir in Treating Chronic Hepatitis B:a Network Meta-analysis
Objective To evaluate therapeutic efficacy of six different proprietary Chinese medicines combined with entecavir in treating chronic hepatitis B(CHB)through network meta-analysis.Methods Randomized controlled trials(RCTs)on proprietary Chinese medicines combined with entecavir for managing hepatitis B were searched in the databases including CNKI,Wanfang,VIP,SinoMed,PubMed,Cochrane Library,Embase,and Web of Science from the establishment to December 23,2023.The quality of included studies was assessed using the Cochrane risk of bias tool,and data analysis was conducted using RevMan 5.4 and Stata 17 software.Results A total of 39 RCTs were included,involving six proprietary Chinese medicines,namely,Fuzheng Huayu capsules,Anluo Huaxian pills,Compound softening liver tablets with turtle shell,Shuganning injection,Gan Shuang granules,and Turtle shell decoction pills.Network meta-analysis revealed that the interventions with the highest cumulative probability area under the curve(SUCRA)in terms of each outcome indicator were as follows:1)for reducing alanine aminotransferase(ALT),Gan Shuang granules plus entecavir;2)for reducing aspartate aminotransferase(AST),Turtle shell decoction pills plus entecavir;3)for reducing hyaluronic acid(HA),Gan Shuang granules plus entecavir;4)for reducing laminin(LN),Fuzheng Huayu capsules plus entecavir;5)for reducing type Ⅲ procollagen N-terminal peptide(P-Ⅲ),Fuzheng Huayu capsules plus entecavir;6)for reducing type Ⅳ collagen(Ⅳ-C),Compound softening liver tablets with turtle shell plus entecavir;7)for reducing total bilirubin(TBIL),Shuganning injection plus entecavir.Conclusion Current evidence suggests that the combination of traditional Chinese medicines with standard entecavir therapy can improve therapeutic efficacy of chronic hepatitis B.
proprietary Chinese medicineentecavirchronic hepatitis Bnetwork meta-analysis
NETL
NSTL
万方数据
